On March 21, Statera Biopharma Inc. (STAB) announced a proposed underwritten public offering. Consequently, the stock took a harsh hit in the after-hours and plunged
Statera Biopharma, Inc. (STAB) is a late-clinical biotherapeutics company focused on the development of innovative immunotherapies aiming at different diseases. The company’s toll-like receptor plays
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.